Welcome to our dedicated page for InMed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on InMed Pharmaceuticals stock.
InMed Pharmaceuticals Inc. reports developments as a pharmaceutical company developing proprietary small-molecule drug candidates for diseases with high unmet medical needs. Its pipeline targets CB1 and CB2 receptors and includes INM-901 for Alzheimer's disease, along with ocular and dermatological programs.
Recurring updates cover financial results, business progress, preclinical and regulatory disclosures, shareholder voting matters, capital actions, Nasdaq listing compliance, and changes affecting BayMedica, its wholly owned subsidiary historically associated with rare cannabinoid commercial activities.
InMed Pharmaceuticals (INM) received a Nasdaq notice that its shareholders' equity of $1,075,007 as of June 30, 2026 is below the $2,500,000 minimum required for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1).
The company attributes the equity decline mainly to transaction expenses tied to its planned merger with Mentari Therapeutics, wind-down costs for subsidiary BayMedica, higher general and administrative expenses, intangible asset impairment charges, and ongoing operating losses. Following the Merger and Mentari’s pre-closing financing, the combined company is expected to receive about $490.0 million in aggregate gross proceeds, which InMed expects will restore compliance with Nasdaq’s equity standard.
InMed has 45 days to submit a compliance plan and may receive up to 180 days to regain compliance. Failure could lead to delisting, with a right to appeal to a Nasdaq Hearings Panel, although there is no assurance of success.
InMed Pharmaceuticals (INM) reported fiscal year 2026 results and highlighted progress on its proposed merger with Mentari Therapeutics, dated September 9, 2026.
The merger agreement signed in May 2026 would create a combined company operating as Mentari Therapeutics and expected to trade under ticker MTRI, focused on migraine prevention. Mentari completed an oversubscribed $290 million private placement in May and a further $200 million round in July, for approximately $490 million in anticipated pre‑closing financing, which the company said should fund operations into 2029 and through Phase 2a readouts of two PACAP‑targeted lead programs. InMed plans to grant legacy shareholders CVRs tied to potential monetization of INM‑901, INM‑089 and INM‑755.
InMed posted a fiscal 2026 net loss of $12.9 million versus $8.2 million a year earlier, with research and development expenses of $3.0 million and general and administrative expenses of $6.7 million. Cash, cash equivalents and short‑term investments fell to $2.2 million at June 30, 2026, from $10.7 million at June 30, 2025. Operations of subsidiary BayMedica were discontinued, with its results presented as discontinued operations.
Mentari Therapeutics, a privately held migraine-focused biotech, announced a $200 million private placement of common stock and pre-funded warrants to leading healthcare investors including Fairmount, ADAR1 Capital Management, Venrock Healthcare Capital Partners, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital and BB Biotech.
According to Mentari, the financing extends its cash runway into 2029, funding Phase 2a readouts for its two PACAP‑targeted lead programs, including MT-002, and supporting the broader migraine prevention pipeline. The placement is expected to close immediately before Mentari’s proposed merger with InMed Pharmaceuticals (Nasdaq: INM) and concurrently with a previously announced $290 million private placement. After the merger and both financings, the combined company, which will operate under the Mentari Therapeutics name and trade on Nasdaq under a new ticker, is expected to have approximately 601,195,812 common shares outstanding on an as-converted / as-exercised basis.
InMed Pharmaceuticals (NASDAQ: INM) amended its definitive all-stock merger agreement with Mentari Therapeutics and filed a Form S-4 registration statement with the SEC.
The amendment clarifies transaction sequencing, the impact of pre-closing financing on the exchange ratio, and intended tax treatment. Boards of both companies have approved the merger, which is expected to close in Q4 2026, subject to shareholder approvals, S-4 effectiveness, and other customary conditions.
InMed Pharmaceuticals (NASDAQ: INM) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing. Nasdaq confirmed INM’s shares closed at or above $1.00 for 10 consecutive business days from May 19 to June 2, 2026, closing the matter.
InMed (NASDAQ:INM) agreed to an all-stock merger with privately held Mentari Therapeutics, creating a Nasdaq-listed company focused on migraine prevention.
A concurrent oversubscribed US$290 million private placement is expected to fund operations through 2028, supporting development of lead antibodies MT-001 and MT-002 with key clinical readouts targeted for 2027–2028.
InMed Pharmaceuticals (NASDAQ: INM) entered a definitive all-stock merger agreement with privately held Mentari Therapeutics to advance migraine prevention therapies. The combined company will operate as Mentari Therapeutics and trade on Nasdaq under a new ticker.
A concurrent oversubscribed US$290 million private placement is expected to fund operations through 2028, supporting first-in-human regulatory filings for lead candidates MT-001 (anti-PACAP) in mid-2026 and MT-002 (anti-CGRP x PACAP bispecific) in Q1 2027, with key clinical readouts targeted for 2027–2028.
InMed Pharmaceuticals (NASDAQ: INM) announced an amendment to certain preferred investment options held by Armistice Capital Master Fund. These options, originally dated October 26, 2023, allow subscription for up to 278,761 common shares.
The exercise price was reduced from $16.60 per share to $0.80 per share. The options were issued via private placement under Section 4(a)(2) of the Securities Act and Regulation D. There is no assurance that any options will be exercised.
InMed (NASDAQ: INM) reported third quarter fiscal 2026 results for the period ended March 31, 2026. The company highlighted new preclinical INM-901 data in human 3D brain organoids showing dose-dependent reductions in IL-6 and IL-8 and alignment with prior in vivo/ex vivo results. The board approved winding down BayMedica commercial operations; discontinued operations generated $0.7M during the quarter. Continuing operations reported a quarterly net loss of $3.0M, R&D of $1.0M, and cash, cash equivalents and short-term investments of $5.2M as of March 31, 2026.
InMed Pharmaceuticals (NASDAQ: INM) amended previously issued preferred investment options with Sabby Volatility Warrant Master Fund and affiliates of H.C. Wainwright to change exercise prices to $0.80 per share. The amendments apply to rights to subscribe for up to 2,151,478 shares (Sabby) and 153,236 shares (Wainwright) on a post-consolidation basis. The options were issued in private placements under Section 4(a)(2) and Regulation D. No assurance any options will be exercised.